TargetMol

AG-13958

Product Code:
 
TAR-T7493
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T7493-1mg1mg£169.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7493-2mg2mg£215.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7493-5mg5mg£351.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7493-1mL1 mL * 10 mM (in DMSO)£352.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7493-10mg10mg£490.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7493-25mg25mg£751.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7493-50mg50mg£1,010.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7493-100mg100mg£1,340.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
AG-13958 (AG-013958), a potent VEGFR tyrosine kinase inhibitor, for the treatment of age-related macular degeneration.
CAS:
319460-94-1
Formula:
C26H22FN7O
Molecular Weight:
467.508
Pathway:
Angiogenesis; Tyrosine Kinase/Adaptors
Purity:
0.9984
SMILES:
Cc1cc(C(=O)Nc2cc(Nc3ccc4c(C=Cc5ccccn5)n[nH]c4c3)ccc2F)n(C)n1
Target:
VEGFR

References

Chappelow A V , Kaiser P K . Neovascular age-related macular degeneration: potential therapies[J]. Drugs, 2008, 68(8):1029-1036. Barakat M R , Kaiser P . VEGF inhibitors for the treatment of neovascular age-related macular degeneration[J]. Expert Opinion on Investigational Drugs, 2009, 18(5):637-646.